Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy

用于放射治疗期间图像引导药物输送的生物材料无人机

• 批准号: 10627008
• 负责人: Wilfred Ngwa
• 金额: $ 19.99万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-08 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10627008
• 关键词: Address; Adoption; Affect; Africa; Africa South of the Sahara; African; African American; African American population; American; Area; Biocompatible Materials; Breast; COVID-19; Cancer Burden; Cancer Center; Cancer Patient; Cessation of life; Clinical Trials; Cost Savings; Country; Dana-Farber Cancer Institute; Data; Economics; Funding; Generations; Goals; Grant; Health Disparities Research; Health Professional; Health Services Accessibility; Human; Immigrant; Incidence; Infrastructure; Investments; Knowledge; Lead; Literature; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Morbidity - disease rate; Multi-Institutional Clinical Trial; National Cancer Institute; Neoplasm Metastasis; Oncology; Outcome; Parents; Patients; Policies; Population; Population Heterogeneity; Professional Organizations; Prostate; Publications; Publishing; Radiation Dose Unit; Radiation therapy; Reporting; Small Business Technology Transfer Research; Survival Rate; Time; Travel; Work; World Health Organization; base; cancer health disparity; conventional therapy; cost; cost effectiveness; data dissemination; disparity reduction; evidence base; global health; health disparity; image-guided drug delivery; innovation; interest; low and middle-income countries; mortality; novel coronavirus; novel strategies; overtreatment; response; success; uptake

Project Abstract This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-22-057. The goal of the NOSI is to stimulate or strengthen global cancer health disparities research. One of the major area of global cancer health disparities is in access to radiotherapy, employed in the treatment of over 50% of cancer patients. According to the recent World Health Organization Cancer Report and Lancet Oncology Commission Report for Sub-Saharan Africa, these disparities are particularly alarming for African populations and may underlie the disparities in access to radiotherapy also seen among African American/immigrant populations in the USA. A greater understanding and innovative approaches to reduce these disparities in access to radiotherapy are crucial in addressing the growing global burden of cancer and disparities in cancer deaths. Innovative approaches with potential to significantly reduce disparities in access to radiotherapy include use of evidence-based hypofractionated radiotherapy (HFRT) and smart radiotherapy biomaterials (SRBs), which are being developed under the parent R01 grant. The SRBs can be employed in place of currently used inert radiotherapy biomaterials (fiducials and beacons). Preliminary studies have established that the SRBs can boost both local and metastatic tumor kill when used in conjunction with HFRT. However, a major gap in the scientific literature is the extent of adoption and utilization of HFRT and radiotherapy biomaterials at African country cancer centers and the currently available infrastructure, including human infrastructure for adoption of such an approach with the SRBs. Hence, in this supplement project, we will investigate disparities in the adoption and utilization of evidence-based HFRT and radiotherapy biomaterials in Africa in comparison with the USA, and potential cost savings that could result in use of HFRT with SRBs. Published data resulting from this project will be crucial in informing policy on increasing access to radiotherapy in Africa. The published data will also be highly relevant in planning USA-Africa multi-center clinical trials resulting from the R01-funded project with participation of diverse populations, including Africans and African Americans traditionally underrepresented in clinical trials. Moreover, the significance of this work is even greater now in global health as COVID-19 has further exposed the level of disparities in access to care, with professional societies recommending increased use of evidence-based HFRT.

项目摘要 该申请是根据已确定的特殊利益通知（NOSI）提交的 作为非CA-22-057。 NOSI的目标是刺激或加强全球癌症健康差异 研究。全球癌症健康差异的主要领域之一是使用放射疗法 在治疗超过50％的癌症患者中。根据最近的世界卫生组织 癌症报告和柳叶刀肿瘤委员会针对撒哈拉以南非洲的报告，这些差异是 非洲人口特别令人震惊，可能是获得放射疗法的差异 在美国的非裔美国人/移民人口中也可以看到。更了解和 减少这些障碍在接受放射疗法方面的创新方法对于解决这个问题至关重要 癌症的全球负担不断增长和癌症死亡的差异。具有潜力的创新方法 大大减少接受放射疗法的差异包括使用基于证据 放射疗法（HFRT）和智能放射疗法生物材料（SRB），正在 根据父级R01赠款开发。 SRB可用于代替当前使用的惰性 放疗生物材料（基准和信标）。初步研究确定了SRB 与HFRT结合使用时，可以增强局部和转移性肿瘤杀死。但是，一个专业 科学文献中的差距是HFRT和放射疗法的采用和利用程度 非洲国家癌症中心和当前可用的基础设施的生物材料，包括人类 通过SRB采用这种方法的基础设施。因此，在这个补充项目中，我们 将研究采用和利用循证HFRT和放射疗法的差异 与美国相比，非洲的生物材料以及可能导致使用的潜在成本 HFRT与SRB。该项目产生的已发布数据对于为有关政策提供了至关重要的 增加非洲的放射疗法的机会。已发布的数据在计划中也将高度相关 由R01资助的项目引起的美国 - 非洲多中心临床试验，参与多样 传统上，包括非洲人和非裔美国人在临床试验中的人口不足。 此外，这项工作的重要性现在在全球健康中更大，因为Covid-19进一步 暴露了获得护理方面的差异水平，专业社会建议增加 使用基于证据的HFRT。